Institut de Neurosciences Cognitives et Intégratives d'Aquitaine (UMR5287)

Aquitaine Institute for Cognitive and Integrative Neuroscience



INCIA - UMR 5287- CNRS
Université de Bordeaux

Zone nord Bat 2 2ème étage
146, rue Léo Saignat
33076 Bordeaux cedex
France

Téléphone 05.57.57.15.51
Télécopie 05.56.90.14.21

Supervisory authorities

CNRS Ecole Pratique des Hautes Etudes Université de Bordeaux

Our partners

Neurocampus Unitéde Formation de Biologie

GDR

GDR Robotique GDR Mémoire GDR Multi-électrodes

Search




Home > Directory

Fernandez Philippe

by Joel Swendsen - published on , updated on

MD, PhD - University Bordeaux Segalen - Professor in Nuclear Medicine

Contact:
philippe.fernandez@u-bordeaux1.fr

Site : Carreire

Team:
Brain Molecular Imaging

Research axis:

  • Positron Emission Tomography for clinical research in oncology and neurology
  • Development of new tracers for PET imaging
  • Imaging processing in PET imaging

Scientific expertise:

  • PET imaging in the oncology field

Projects:

  • My research focuses on clinical applications for PET imaging in oncology and neurology. We have created with Professor Michele Allard a PET clinical unit with a PET-CT imager dedicated to research and a radiochemistry laboratory in close proximity to this unit in strong partnership with the private sector (IBA-CisBio). With the chemists and radiochemists in our team, we synthesize and develop new PET and SPECT tracers for neoangiogenesis imaging (RGD ligands radiolabeled with fluorine 18 or technetium 99m), proliferation imaging (18F-FLT), hypoxia imaging (18F-FMISO), and MMP imaging to propose new agents to better select the patients and to follow them for new targeted therapies. Our team also works in developing new methods for synthesis of radiolabeled oligonuclotids. We are conducting different clinical trials concerning brain, head and neck tumors, and we are participating in different clinical trials in neurology with PET tracers of cerebral metabolism as well as tracers of beta-amyloid plaques in neurodegenerative diseases. We are also interested in novel techniques of PET acquisition in the radiotherapy field to introduce into image processing different corrections in terms of motion, partial volume effects but also relative to segmentation to improve delineation of target volumes.

Selected Publications:

  • HUCHET A, LAMARE F., MELLA C., BENECH J., DE CLERMONT H, MAIRE J.P., LOISEAU H., FERNANDEZ P. “Interest of [18F]-Fluoromisonidazole-Positron Emission Tomography for Hypoxia Target Volumes for Radiotherapy Planning in malignant gliomas.” International journal of radiation oncology biology physics, 2011, soumis pour publication.
  • DE CLERMONT H, HUCHET A, LAMARE F, RIVIERE A, FERNANDEZ P. “Lack of concordance between the [18f]-fluoromisonidazole PET and the [18f]-FDG –PET in human glioblastom”. Clin Nucl Med, 2011, xx: xx-xx, sous presse
  • HUCHET A, FERNANDEZ P, ALLARD M, BELKACEMI Y, MAIRE JP, TROUETTE R, EIMER S, TOURDIAS T, LOISEAU H. « Molecular Imaging of tumour hypoxia ». Cancer radiotherapie, 2009, 13 : 747-757.
  • FARID K., SIBON I., FERNANDEZ P., GUYOT M., JEANDOT R. AND ALLARD M. “Delayed acquisition and hyperglycemia improve brain metastasis detection on 18F-FDG-PET”, Clin Nucl Med, 2009, 34(9): 634-635.
  • HENRIQUES DE FIGUEIREDO B, BARRET O, DEMEAUX H, LAGARDE P, DE-MONES-DEL-PUJOL E, SIBERCHICOT F, MAIRE J-P, RICHAUD P, ALLARD M, FERNANDEZ P. « Comparison between CT and 18F-Fluoro-désoxy-glucose ([18F]-FDG) defined target volumes for radiotherapy planning in head and neck cancers”. Radiotherapy and Oncology, 2009, 93(3): 479-82.
  • GODBERT Y, DE CLERMONT H, WALLERAND H, LAFFON E, FERRIERE JM, RAVAUD A, ALLARD M, FERNANDEZ F. « La tomographie par émission de positons couplée à la tomodensitométrie (TEP-TDM) au 18F-FDG avec dilution vésicale dans l’imagerie des tumeurs urothéliales. A propos de quatre cas. ». Médecine Nucléaire, 2009, 33: 216-22.
  • LAFFON E, CAZEAU AL, MONET A, DE CLERMONT H, FERNANDEZ P, MARTHAN R, DUCASSOU D. “The effect of renal failure on 18F-FDG uptake: a theoretical assessment”. J Nucl Med Tech, 2008, 36: 200-202.
  • RICARD AS, GINDRE A, LAURENTJOYE M, FERNANDEZ P, GUYOT M, DEMEAUX H, SIBERCHICOT F, MAJOUFRE-LEFEBVRE C. « Role of PET-CT with 18-FDG in the management of UADT squamous-cell carcinomas: A retrospective study of 43 cases”. Rev Stomatol Chir Maxillofac, 2008, 109(2):86-90.
  • QUENEAU M, TOURDIAS T, GUYOT M, HOULIAT T, ALLARD M AND FERNANDEZ P. « Impact thérapeutique de l’acquisition cervicale dédiée en [18 F]-FDG-TEP-TDM sur la prise en charge des carcinomes épidermoïdes de la tête et du cou ».Médecine nucléaire, 2008, 32, 9 : 473-481.
  • RIVIERE A, DE CLERMONT H, FARID K, GUYOT M, JEANDOT R, DAUCHY F, ALLARD M, DUPON M, FERNANDEZ P. “Intérêt de l’imagerie hybride TEMP-TDM dans l’exploration des infections”. Médecine Nucléaire 2008 Mar; (32) :146-153.
  • EL BADAOUI A, DE CLERMONT H, VALLI N, CAIGNON JM, FERNANDEZ P, ALLARD M, BARAT JL, DUCASSOU D. “Impact diagnostique de la TEMP-TDM dans l’exploration des tumeurs endocrines”. Médecine Nucléaire, 2008 Feb (32): 66-75.